TLR8 and cancer: Functional assays in LUAD cells and macrophages treated with the TLR8 agonist Motolimod examined proliferation, migration, invasion, phagocytosis, mitochondrial activity, and ROS generation.<h4>Results</h4>TLRs showed altered expression, frequent mutations, copy number variations, and methylation regulation in cancer.